SCNX_OUT_1 [2025-03-19 15:37:53 -0400] 2732 Bytes | 740 tokens | Cum: 740 tkns (9.25% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Scienture (SCNX) hit my radar screen, up to 1.88 from a prev close of 1.59 Do you think its got more juice or is it lacking potential? It's 03:37:51 PM on Wednesday March 19, 2025 ET (UTC-0400) and I have to decide: buy or sell!

Here's the first list of news for Scienture:

C1 - Today 08:05AM - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
C2 - Mar-18-25 08:05AM - SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
C3 - Mar-06-25 07:40AM - SCIENTURE to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
C4 - Jan-21-25 08:05AM - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
C5 - Dec-17-24 08:05AM - Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
C6 - Dec-10-24 08:05AM - Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
C7 - Nov-26-24 04:05PM - Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement
C8 - Sep-24-24 08:01AM - TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to SCNX

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Scienture (SCNX)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Scienture.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

SCNX_OUT_3 [2025-03-19 15:37:55 -0400] 970 Bytes | 303 tokens | Cum: 1045 tkns (13.06% of 8k)
==========================================================================

Showing C2 (chunk 1 of 12): C2:
**SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.**
Date: Mar-18-25 08:05AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/18/3044475/0/en/SCIENTURE-announces-the-U-S-FDA-Approval-of-its-NDA-for-SCN-102-to-be-launched-as-ArbliTM-losartan-potassium-Oral-Suspension-10mg-mL-The-global-market-for-losartan-potassium-was-ap.html

March 18, 2025 08:05 ET| Source:Scienture Holdings, Inc.Scienture Holdings, Inc.

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- –SCIENTURE HOLDINGS, INC.NASDAQ: SCNX),a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to

-- More? (MOR) or Next section? (NEX)

SCNX_OUT_5 [2025-03-19 15:37:57 -0400] 968 Bytes | 220 tokens | Cum: 1267 tkns (15.84% of 8k)
==========================================================================

Showing C2 (chunk 2 of 12): market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc., with the brand nameArbliTM(losartan potassium) Oral Suspension, 10 mg/mL.ArbliTMis meant for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes.ArbliTMis the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market.

ArbliTMis a novel proprietary formulation of losartan, a proven therapy for treating hypertension, which provides a tailored approach to patients that require or prefer an oral

-- More? (MOR) or Next section? (NEX)

SCNX_OUT_7 [2025-03-19 15:37:59 -0400] 1039 Bytes | 298 tokens | Cum: 1572 tkns (19.65% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T17:06:06Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Biodexa Pharmaceuticals (NASDAQ:BDRX)...
A2 - 2025-03-19T12:23:21Z - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Sha...
A3 - 2025-03-19T12:16:04Z - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Sha...
A4 - 2025-03-19T12:16:26Z - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Sha...
A5 - 2025-03-19T12:15:32Z - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Sha...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SCNX_OUT_9 [2025-03-19 15:38:01 -0400] 967 Bytes | 293 tokens | Cum: 1867 tkns (23.34% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Wednesday's Intraday Session - Biodexa Pharmaceuticals (NASDAQ:BDRX), Black Diamond Therapeutic (NASDAQ:BDTX)**Date: 2025-03-19Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44402165/12-health-care-stocks-moving-in-wednesdays-intraday-sessionGainers

Black Diamond Therapeutic BDTX stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million. Lyell Immunopharma LYEL shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million. Biodexa Pharmaceuticals BDRX shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million. TuHURA Biosciences HURA shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million. Venus Concept

-- More? (MOR) or Next section? (NEX)

SCNX_OUT_11 [2025-03-19 15:38:02 -0400] 440 Bytes | 120 tokens | Cum: 1989 tkns (24.86% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-21T13:05:00Z - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCNX_OUT_13 [2025-03-19 15:38:16 -0400] 717 Bytes | 199 tokens | Cum: 2190 tkns (27.38% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/21/3012635/0/en/Scienture-Holdings-Inc-Announces-Dr-Narasimhan-Mani-s-Participation-in-the-8th-Annual-Conference-of-The-Society-for-the-Study-of-Xenobiotics.htmlScienture Holdings, Inc., a specialty pharmaceutical company, announced that its President, Dr. Narasimhan Mani, will participate as a speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics in India.

-- More? (MOR) or Next section? (NEX)

SCNX_OUT_15 [2025-03-19 15:38:17 -0400] 1144 Bytes | 316 tokens | Cum: 2747 tkns (34.34% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agrmt (the Agrmt) with Summit Biosciences Inc., a wholly-...

S2 - 2025-03-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agrmt (the Agrmt) with Summit Biosciences Inc., a wholly-...

S3 - 2025-03-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agrmt (the Agrmt) with Summit Biosciences Inc., a wholly-...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

SCNX_OUT_17 [2025-03-19 15:38:19 -0400] 967 Bytes | 237 tokens | Cum: 2986 tkns (37.33% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01. Entry into a Material Definitive Agreement.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agreement (the Agreement) with Summit Biosciences Inc., a wholly-owned subsidiary of Kindeva Drug Delivery L.P. (Kindeva). Kindeva is a company engaged in the research, development, and manufacturing of pharmaceutical products. Pursuant to the Agreement, Kindeva granted the Company an exclusive, non-transferrable, non-sublicensable right and license to commercialize REZENOPY (Nalaxone HCI Nasal spray 10mg/0.11mL) (the Product) within the United States and its territories. The Company intends to use the exclusive right and license to price, launch, promote, market, distribute, and educate the public on the Product.

Unless earlier terminated, the term of the Agreement will

-- More? (MOR) or Next section? (NEX)

SCNX_OUT_19 [2025-03-19 15:38:21 -0400] 967 Bytes | 198 tokens | Cum: 3186 tkns (39.83% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): remain in effect for 10 years from the date of first commercial sale of the Product in the United States and its territories to an unaffiliated third-party. The Agreement will automatically renew for successive 1-year periods unless either party terminates the agreement in accordance with its terms. Either party may terminate the Agreement if (i) the other party materially breaches the Agreement and has not cured such breach during a period of 90 days following notice of the breach, (ii) the Product is withdrawn from the market as a result of any ruling or requirement by the United States Food and Drug Administration (the FDA), a voluntary recall by the FDA is issued, or there are material safety concerns that could significantly impact the commercial viability of the Product, or (iii) the Product is the subject of a mass tort liability action or is subject to material health and public

-- More? (MOR) or Next section? (NEX)

SCNX_OUT_21 [2025-03-19 15:38:39 -0400] 3194 Bytes | 783 tokens | Cum: 3976 tkns (49.70% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+
| Prev Close: 1.59 | RSI (14): 42.70 | Perf Quarter: -75.84% | Insider Trans: 0.00% | Sales Q/Q: -96.85% | ROE: -47.91% |
+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+
| Target Price: 6.75 | ATR (14): 0.54 | Index: - | Option/Short: No / No | Sales past 5Y: 18.09% | ROI: -28.75% |
+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+
| Price: 1.89 | SMA20: -10.69% | Market Cap: 16.99M | Short Float: 0.36% | Income: -25.17M | Sales Surprise: 9.28% |
+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+
| Change: 18.81% | SMA50: -42.77% | Shs Outstand: 8.61M | Short Ratio: 0.01 | Employees: 8 | EPS Surprise: -286.67% |
+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+
| Volume: 17,633,884 | SMA200: -73.87% | Shs Float: 4.62M | Short Interest: 0.02M | Debt/Eq: 0.03 | P/E: - |
+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+
| Avg Volume: 2.52M | Perf Week: 49.92% | Inst Own: 1.04% | Beta: 2.76 | Sales Y/Y TTM: -73.19% | Earnings: - |
+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+
| Rel Volume: 7.70 | Perf Month: -39.99% | Insider Own: 48.62% | Sales: 2.44M | Profit Margin: -1033.40% | |
+--------------------+---------------------+-----------------------+-----------------------+--------------------------+------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

SCNX_OUT_23 [2025-03-19 15:38:41 -0400] 561 Bytes | 131 tokens | Cum: 4409 tkns (55.11% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SCNX_IN_25 [2025-03-19 15:38:42 -0400] 126 Bytes | 29 tokens | Cum: 4445 tkns (55.56% of 8k)
==========================================================================

====================================
[2025-03-19 12:38:42] # Analysis Completed
Elapsed Time: 51.44 seconds